Drug Information

Drug General Information
Drug ID
D06NEB
Former ID
DNC006565
Drug Name
Ac-hPhe-Leu-Phe-LeuVSMe
Drug Type
Small molecular drug
Indication Discovery agent Investigative [528196]
Formula
C35H50N4O6S
Canonical SMILES
CC(C)CC(C=CS(=O)(=O)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC(C<br />)C)NC(=O)C(CCC2=CC=CC=C2)NC(=O)C
InChI
1S/C35H50N4O6S/c1-24(2)21-29(19-20-46(6,44)45)37-34(42)32(23-28-15-11-8-12-16-28)39-35(43)31(22-25(3)4)38-33(41)30(36-26(5)40)18-17-27-13-9-7-10-14-27/h7-16,19-20,24-25,29-32H,17-18,21-23H2,1-6H3,(H,36,40)(H,37,42)(H,38,41)(H,39,43)/b20-19+/t29-,30+,31+,32+/m1/s1
InChIKey
UIUWSHIRBDIYGM-QLEUBDALSA-N
PubChem Compound ID
11693148
Target and Pathway
Target(s) Cathepsin B Target Info Inhibitor [528196]
Cathepsin S Target Info Inhibitor [528196]
KEGG Pathway Lysosome
Antigen processing and presentationhsa04142:Lysosome
Phagosome
Antigen processing and presentation
Tuberculosis
NetPath Pathway TCR Signaling Pathway
IL2 Signaling PathwayNetPath_22:Leptin Signaling Pathway
IL2 Signaling Pathway
Reactome Collagen degradation
Trafficking and processing of endosomal TLR
Assembly of collagen fibrils and other multimeric structures
MHC class II antigen presentationR-HSA-1236977:Endosomal/Vacuolar pathway
Degradation of the extracellular matrix
MHC class II antigen presentation
WikiPathways Class I MHC mediated antigen processing & presentation
Trafficking and processing of endosomal TLR
References
Ref 528196J Med Chem. 2006 May 18;49(10):2953-68.Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
Ref 528196J Med Chem. 2006 May 18;49(10):2953-68.Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.